

FOI 1745

28.06.2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma :

- **Avelumab + Axitinib**
- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Ipilimumab monotherapy**
- **Lenvantinib + Everolimus**
- **Nivolumab monotherapy**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab + Axitinib**
- **Pembrolizumab + Lenvatinib**
- **Pembrolizumab monotherapy**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib AND Trametinib**
- **Dacarbazine**
- **Encorafenib AND Binimetinib**

- **Ipilimumab**
- **Ipilimumab AND Nivolumab**
- **Nivolumab**
- **Pembrolizumab**
- **Trametinib**
- **Vemurafenib**
- **Vemurafenib AND Cobimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

**Q3. Does you trust participate in any clinical trials for the treatment of Melanoma?
If so please provide the name of each trial and number of patients that are taking part?**

This information is not held.

Email: Foi.Team@Southerntrust.hscni.net